Abstract
Purpose. To design a controlled release 5-fluorouracil (5-FU) implant to provide prolonged antifibroblast concentrations of 5-FU in the sub-conjunctival tissues but low concentrations of 5-FU in other ocular tissues.
Methods. Implants (5 mg; 2.5 mm diameter × 1.2 mm thickness) of 5-FU or 9:1, 8:2, 7:3 5-FU to polymer mass ratios were made by compression. Poly(D,L-lactide-co-glycolide) polymers with 50:50 and 75:25 lactide to glycolide ratios were used. In vitro release characteristics of four types of implants were studied: 5-FU alone (CT), 5-FU/ polymer matrices (MT), coated 5-FU/polymer matrices with a central hole drilled through the matrix and coating (CM1), and with a central hole in the coating (CM2). MT and CM1 (9:1 drug/polymer) were selected for subconjunctival implantation in rabbits. 14C-5-FU levels in various ocular tissues and retrieved pellets were monitored.
Results. First-order release was observed from CT, MT and CM1 implants. Zero-order release profiles were observed from CM2 implants. Drug release was retarded by formulating 5-FU in a matrix comprising poly(D,L-lactide-co-glycolide) which in turn could be modified by the lactide/glycolide ratio of the polymer, the drug to polymer ratio, coating, and hole dimensions. First-order release kinetics were observed for MT and CM1 implants in the in vivo study in rabbits. A correlation between in vitro and in vivo release was established which allowed in vivo release to be predicted from in vitro release data. For CM1, therapeutic tissue concentrations of 35.2 µg/g (conjunctiva) and 17.7µLg/g (sclera) were found at the implantation site up to 200 hours post-implantation. Tracer levels were undetectable in other ocular tissues.
Conclusions. The CM1 implant maintained steady antifibroblast levels in target tissues and minimized levels in nontarget tissues.
Similar content being viewed by others
REFERENCES
D. K. Heuer, R. K. I. Parrish, M. G. Gressel, E. Hodapp, P. F. Palmberg, and D. P. Anderson. 5-fluorouracil and glaucoma filtering surgery II: A pilot study. Ophthalmol. 91:384–394 (1984).
M. G. Gressel, R. K. I. Parrish, and R. Folberg. 5-fluorouracil and glaucoma filtering surgery: I. An animal model. Ophthalmol. 91:378–383 (1984).
A. Ophir and U. Ticho. Encapsulated filtering bleb and subconjunctival 5-fluorouracil. Ophthalmic Surg. 23:339–341 (1992).
B. Wolner, J. M. Liebmann, J. W. Sassani, R. Ritch, M. Speaker, and M. Marmor. Late bleb-related endophthalmitis after trabeculectomy with adjunctive 5-fluorouracil. Ophthalmol. 98:1053–1060 (1991).
R. N. Weinreb. Adjusting the dose of 5-fluorouracil after filtration surgery to minimise side effects. Ophthalmol. 94:564–570 (1987).
A. Ophir and U. Ticho. Toxic effect of 5-fluorouracil on fibroblasts following trabeculectomy. Ophthalmic Res. 24:298–302 (1992).
D. A. Lee, P. Hersh, D. Kersten, and S. Melamed. Complications of subconjunctival 5-fluorouracil following glaucoma filtering surgery. Ophthalmic Surg. 18:187–190 (1987).
N. Nao-i and Y. Honda. Toxic effect of fluorouracil on the rabbit retina. Am. J. Ophthalmol. 96:641–643 (1983).
P. T. Khaw, S. Ward, A. Porter, I. Grierson, R. A. Hitchings, and N. S. Rice. The long-term effects of 5-fluorouracil and sodium butyrate on human Tenon's fibroblasts. Invest. Ophthalmol. Vis. Sci. 33:2043–2052 (1992).
B. K. Lowe. Personal communication with Birmingham Polymers, Inc. Birmingham, USA (1995).
C. Chiang and R. D. Schoenwald. Ocular pharmacokinetic models of clonidine-3H hydrochloride. J. Pharmacokinet. Biopharm. 14:175–211 (1986).
J. G. Wagner. Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules. J. Pharm. Sci. 58:1253–1257 (1969).
M. Gibaldi and S. Feldman. Establishment of sink conditions in dissolution rate determinations: theoretical considerations and application to nonodistingrating dosage forms. J. Pharm. Sci. 56:1238–1242 (1967).
R. D. Purves. A macintosh application for non-linear parameter estimation. Department of pharmacology, University of Otago, Dunedin, 1992.
K. Yamaoka, T. Nakagawa, and T. Uno. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165–175 (1978).
G. L. Skuta and R. K. I. Parrish. Wound healing in glaucoma filtering surgery. Surv. Ophthalmol. 32:149–170 (1987).
E. J. Rockwood, P. K. Parrish, D. K. Heuer, G. L. Skuta, E. Hodapp, P. F. Palmberg, M. G. Gressel, and W. Feuer. Glaucoma filtering surgery with 5-fluorouracil. Ophthalmol. 94:1071–1078 (1987).
S. T. Simmons, M. B. Sherwood, D. A. Nichols, R. B. Penne, T. Sery, and L. Spaeth. Pharmacokinetics of a 5-fluorouracil liposomal delivery system. Br. J. Ophthalmol. 72:688–691 (1988).
I. Finkelstein, G. E. Trope, J. G. Heathcote, D. S. Rootman, L. Spero, and I. A. Menon. Further evaluation of collagen shields as a delivery system for 5-fluorouracil: histopathological observations. Can. J. Ophthalmol. 26:129–132 (1991).
T. J. Smith, M. B. Maurin, S. M. Milosovich, and A. Hussain. Polyvinyl alcohol membrane permeability characteristics of 5-fluorouracil. J. Ocul. Pharmacol. 4:147–152 (1987).
P. E. Rubsamen, P. A. Davis, E. Hernandez, G. E. O'Grady, and S. W. Cousins. Prevention of experimental proliferative vitreoretionopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch. Ophthalmol. 112:407–413 (1994).
M. S. Hora, R. K. Rana, J. H. Nunberg, T. R. Tice, R. M. Gilley, and M. E. Hudson. Release of human serum albumin from poly(-lactide-co-glycolide) microspheres. Pharm. Res. 7:1190–1194 (1990).
R. A. Siegel. Modelling of drug release from porous polymers. In M. Rosoff (ed), Controlled Release of Drugs: polymer and aggregate systems, VCH Publishers Inc., New Youk, 1989, pp. 1–52.
D. Brooke and R. J. Washkuhn. Zero-order drug delivery system: theory and preliminary testing. J. Pharm. Sci. 66:159–162 (1977).
D. S. Hsieh, W. D. Rhine, and R. Langer. Zero-order controlled-release polymer matrices for micro-and macromolecules. J. Pharm. Sci. 72:17–22 (1983).
D. S. Mishra and S. H. Yalkowsky. A flat circular hole device for zero-order release of drugs: characterisation of the moving dissolution boundary. Pharm. Res. 7:1195–1197 (1990).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wang, G., Tucker, I.G., Roberts, M.S. et al. In Vitro and in Vivo Evaluation in Rabbits of a Controlled Release 5-fluorouracil Subconjunctival Implant Based on Poly(D,L-lactide-co-glycolide). Pharm Res 13, 1059–1064 (1996). https://doi.org/10.1023/A:1016062825360
Issue Date:
DOI: https://doi.org/10.1023/A:1016062825360